Alzheimer's disease: emerging noncholinergic treatments.
With population trends skewing toward a larger percentage of elderly, Alzheimer's disease is projected to afflict many millions in the United States and around the world in the next 50 years. In terms of cost and psychological burden, the anticipated burden of this disease on caregivers and society at large is staggering. It is hoped that, with the development of new insights into the processes of this devastating illness and the development of new medications that may interrupt those processes, the projected incidence and impact of AD may be modified in the near future.
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D017281:Cost of Illness; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use; D020441:Ginkgo biloba / Q000502:physiology; D006801:Humans; D008559:Memantine / Q000627:therapeutic use; D017063:Outcome Assessment, Health Care; D008517:Phytotherapy; D011322:Primary Prevention / Q000379:methods; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors; D013619:Tacrine / Q000627:therapeutic use; D014481:United States / Q000453:epidemiology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000975:Antioxidants; D002800:Cholinesterase Inhibitors; D018691:Excitatory Amino Acid Antagonists; D016194:Receptors, N-Methyl-D-Aspartate; D013619:Tacrine; D008559:Memantine